← Volver a la portada
Estados Unidos · Plataformas y datos · Yahoo Finance

J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports

Publicado por Yahoo Finance · Estados Unidos hace 10 h
J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
Yahoo Finance

Resumen detallado

Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial…

Investing.com-- Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.

The deal could involve an upfront cash payment of $2.2 billion and up to $1.2 billion in milestone payments, although discussions could still fall apart, the report said.

Stop chasing stocks after they've already rallied. Find your next investment opportunity with AI stock picks, earnings insights, and market-moving news. Yahoo! Finance readers get an extra 15% off on top of the 55% off Black Friday price. Join today! »

Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing OLN324, a drug targeting wet age-related macular degeneration and diabetic macular oedema, two leading causes of severe vision loss. The treatment is expected to enter late-stage clinical trials.

The acquisition would expand J&J's presence in retinal disease treatments, an area where it has limited exposure despite its contact lens business.

The potential deal comes amid a record year for biotech acquisitions, with 46 companies valued at more than $1 billion sold so far, surpassing the previous annual record of 35, according to investment bank Stifel, the FT reported.

J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

También te puede interesar